#Sola #FastWave Medical #Artero

FastWave Medical's Recent Patent Acquisition

FastWave Medical, a pioneering company in intravascular lithotripsy (IVL) technology, recently announced that it has added four new international patents to its growing portfolio, bringing the total count to 13 patents worldwide, including nine in the United States. This development significantly strengthens FastWave's intellectual property, which is critical as the company gears up for clinical trials targeting peripheral and coronary artery diseases.

The newly granted patents include two issued in Australia and two in Japan, covering both of FastWave's key platforms — Artero™, an electric IVL system designed for peripheral artery disease (PAD), and Sola™, its laser-based IVL system aimed at combating coronary artery disease (CAD).

Tristan Tieso, COO of FastWave Medical, expressed enthusiasm about the expanded patent protections, stating, “This latest expansion of our patent portfolio strengthens the global protection around both Artero™ and Sola™, and reflects the depth of innovation behind FastWave's dual-platform IVL strategy.” Tieso emphasized that these patents play a crucial role in protecting FastWave's technology as they venture into prospective Investigational Device Exemption (IDE) trials.

Growing Interest in Intravascular Lithotripsy

In recent years, IVL has emerged as a preferred treatment option for calcific artery disease, capturing the attention of interventional cardiologists. Despite the advantages that IVL offers, first-generation systems still face challenges in terms of speed, control, usability, and adaptability in various procedural settings. FastWave Medical is working hard to bridge these gaps as it advances its next-generation IVL technologies for both peripheral and coronary applications.

Dr. Miguel Montero-Baker, CEO and Medical Director at the HOPE Amputation Prevention Center, acknowledged the difficulties posed by calcified artery disease, remarking, “Calcified arterial disease remains one of the most difficult challenges in interventional medicine, particularly when calcium limits device delivery and procedural efficiency.” He believes that as IVL adoption grows, physicians will increasingly seek technologies that facilitate fast, predictable, and integrated calcium modification.

Recognition and Future Goals

The patent milestone for FastWave Medical builds on a series of recent honors and clinical advancements. The company was recognized as one of **Fierce Medtech's 2024